No Data
Summit Therapeutics Outlines Ivonescimab Progress With Key Phase III Data Expected Mid-2025
Summit Therapeutics Non-GAAP EPS of -$0.07 Beats by $0.02
Summit Therapeutics Q1 Loss Widens; Cash Equivalents Drop
Earnings Flash (SMMT) Summit Therapeutics Q1 Adjusted Loss $0.07 Vs. $0.05 Loss Year Ago
Summit Therapeutics | 10-Q: Quarterly report
Express News | Summit Therapeutics Q1 Operating Expenses USD 66.8 Million